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The Luminex Single-Antigen Beads (LSA) assay allows an accurate detection and
characterization of pre-existing HLA antibodies (Ab) in kidney transplant candidates. HLA
specificities are determined against which the patient has circulating alloantibodies that are
expected to harm a transplanted organ. With this characterization, it is possible to reliably
predict crossmatch results for a given donor, the so called virtual crossmatch (vXM). The
vXM is commonly used by many transplantation centers in the selection of potential
candidates for kidney transplant from a deceased donor and transplantation of candidates
with preformed anti-HLA donor specific Ab is usually avoided [2].
Before the introduction of the LSA technique those antibodies were determined using the
complement-dependent cytotoxicity (CDC) methodology which have a lot lower sensitivity to
detect clinically relevant anti-HLA antibodies. Panel reactive antibody (PRA) determined by
CDC gives us a perceptual value used to estimate the percentage of future donors to which
a candidate will have a positive CDC crossmatch. As an alternative to this PRA-CDC some
transplantation centers use the so called calculated PRA (cPRA) representing the
percentage of actual organ donors that express 1 or more of unacceptable HLA antigens [3].
CPRA more accurately reflects the probability of a candidate to receive a transplant and can
assist in the selection of the best transplant approach. Phenotype frequencies used for the
cPRA calculation must be in accordance (as much as possible) to those from future donors
for kidney transplantation, in order to be useful for sensitization measurements and organ-
allocation algorithms. The cPRA, rather than PRA by CDC (an inaccurate measure), should
be used simultaneously with vXM to seek and increase accessibility and promote equity to
all patients awaiting kidney transplantation.
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The demand for kidneys for transplantation grows daily due to the successful treatment of
many patients with end stage renal disease. The success of kidney transplants depends
largely on genetic and immunological compatibility between the organ and its recipient. An
important barrier to kidney transplantation is the sensitization of transplant candidates to
human leukocyte antigen (HLA) [1].
Using cPRA and vXM simultaneously
